SARS-CoV-2 S1 (RBD) Mu B.1.621 (Columbia), GFP/His-Tag Tags_BFP Purity: > 90% as determined

Purity: > 90% as determined by SDS-PAGE

BAFF has emerged as a promising therapeutic target for the treatment of autoimmune disorders and B-cell malignancies

especially cancer and autoimmune diseases

In clinical assays

It is recommended to improve cleavage efficiency for each fusion protein by varying the amount of recombinant blueTEV

SARS-CoV-2 S1 (RBD) Mu B.1.621 (Columbia), GFP/His-Tag Tags_BFP Purity: > 90% as determinedRecombinant protein of the receptor binding domain (RBD), Mutant (R346K, E484K, N501Y) of SARS CoV 2 (COVID 2019) spike S1 from Wuhan pneumonia virus with C terminal GFP His tag. The mutations R346K, E484K, and N501Y are identified in the SARS CoV 2 virus variant B. 1. 621, which emerged in South America and was first reported in Colombia in January 2021. B. 1. 621 classified as Variant of Interest (VOI) and also known as Mu variant. The mutations are